This proposal describes a plan to study frontotemporal lobar degeneration (FTLD) using the infrastructure established by the Alzheimer's Disease Neuroimaging Initiative (ADNI). FTLD is a common cause of dementia, especially in patients under the age of 65, with large economic and social costs. Over the next few years, potential therapeutic agents for FTLD will likely emerge and require clinical testing. In preparation for these clinical trials, it is important to establish precise, reliable and cost-effective markers for disease progression, to maximize the power of treatment trials to detect disease modifying effects. In the proposed study, 120 patients with FTLD and 120 age-matched controls will be studied with MRI, FDG-PET, and blood, urine and CSF biomarkers over the course of one year to determine the best regions and best methods for following the progression of FTLD. All patients will also undergo PIB-PET scanning, which identifies beta-amyloid plaques associated with Alzheimer's disease.
The specific aims of the study are: 1) To identify the regions where FTLD shows greatest longitudinal changes in glucose metabolism, cerebral perfusion, and gray matter volume with the lowest variance, 2) To identify regions where FTLD shows greatest longitudinal changes with lowest variance in white matter tract integrity, 3) To contrast the performance of FDG-PET, ASL perfusion, gray matter volume and white matter tract integrity to detect longitudinal changes in FTLD, 4) To establish the clinical correlates of longitudinal changes in glucose metabolism, perfusion, gray matter volume and white matter integrity in FTLD, 5) To quantify the changes in CSF tau and A-beta1-42 levels and tau/abeta ratios over time in FTLD, and 6) To define the metabolic, structural imaging and CSF biomarker features predicting increased PIB retention with a clinical diagnosis of FTLD. Should these aims be achieved, the proposed study would provide firm data about which regions are the most sensitive indicators for following the course of disease in FTLD, and whether PET is significantly better than MRI for this purpose or visa-versa. The data would also provide estimates from which power could be calculated for clinical studies. All the data will eventually be available in a publicly accessible database for use by other researchers.

Public Health Relevance

The frontotemporal lobar degeneration (FTLD) neuroimaging initiative will provide information on how to use brain images to follow the course of FTLD over time, and what techniques are best for this purpose. This information will be valuable to researchers planning trials of new medications for FTLD, so they can use brain imaging to help decide which drugs show the most promise for treating the disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG032306-03
Application #
8121405
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Hsiao, John
Project Start
2009-09-30
Project End
2014-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
3
Fiscal Year
2011
Total Cost
$2,034,064
Indirect Cost
Name
University of California San Francisco
Department
Neurology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Staffaroni, Adam M; Elahi, Fanny M; McDermott, Dana et al. (2017) Neuroimaging in Dementia. Semin Neurol 37:510-537
Lee, Suzee E; Sias, Ana C; Mandelli, Maria Luisa et al. (2017) Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin 14:286-297
Yokoyama, Jennifer S; Karch, Celeste M; Fan, Chun C et al. (2017) Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathol 133:825-837
Watson, Christa L; Possin, Katherine; Allen, I Elaine et al. (2017) Visuospatial Functioning in the Primary Progressive Aphasias. J Int Neuropsychol Soc :1-10
Spina, Salvatore; Schonhaut, Daniel R; Boeve, Bradley F et al. (2017) Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations. Neurology 88:758-766
Spinelli, Edoardo G; Mandelli, Maria Luisa; Miller, Zachary A et al. (2017) Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol 81:430-443
Perry, David C; Datta, Samir; Sturm, Virginia E et al. (2017) Reward deficits in behavioural variant frontotemporal dementia include insensitivity to negative stimuli. Brain 140:3346-3356
Brown, Jesse A; Hua, Alice Y; Trujllo, Andrew et al. (2017) Advancing functional dysconnectivity and atrophy in progressive supranuclear palsy. Neuroimage Clin 16:564-574
Perry, David C; Brown, Jesse A; Possin, Katherine L et al. (2017) Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain 140:3329-3345
Elahi, Fanny M; Marx, Gabe; Cobigo, Yann et al. (2017) Longitudinal white matter change in frontotemporal dementia subtypes and sporadic late onset Alzheimer's disease. Neuroimage Clin 16:595-603

Showing the most recent 10 out of 104 publications